{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:50:44Z","timestamp":1791903044244,"version":"4.3.4"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":256,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>This phase II trial was performed to evaluate the efficacy of a new granulocyte colony\u2010stimulating factor (G\u2010CSF)\u2010supported multi\u2010agent chemotherapy protocol, LSG15, for aggressive adult T\u2010cell leukaemia\u2010lymphoma (ATL). Ninety\u2010six previously untreated patients with aggressive ATL were enrolled and grouped as: acute type (58), lymphoma type (28) and unfavourable chronic type (10). Therapy consisted of seven cycles of VCAP (vincristine, cyclophosphamide, doxorubicin and prednisone), AMP (doxorubicin, ranimustine and prednisone) and VECP (vindesine, etoposide, carboplatin and prednisone). G\u2010CSF was administered during the intervals between chemotherapy until neutrophil reconstitution was achieved. Eighty\u2010one per cent of the 93 eligible patients responded [95% confidence interval (CI), 71\u00b71\u201388\u00b71%], with 33 patients obtaining complete response (35\u00b75%) and 42 obtaining partial response (45\u00b72%). The median survival time (MST) after registration was 13\u2003months and the median follow\u2010up duration of the 20 surviving patients was 4\u00b72\u2003years (range 2\u00b78\u20135\u00b76). Overall survival at 2\u2003years was estimated to be 31\u00b73% (95% CI, 22\u00b70\u201340\u00b75%). Grade 4 haematological toxicity of neutropenia and thrombocytopenia were observed in 65\u00b73% and 52\u00b76% of the patients respectively, but grade 4 non\u2010haematological toxicity was observed in only one patient. LSG15 is feasible with mild non\u2010haematological toxicity and improved the clinical outcome of ATL patients. MST and overall survival at 2\u2003years were superior to those obtained by our previous trials.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02737.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T10:27:39Z","timestamp":1027679259000},"page":"375-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":294,"title":["A new G\u2010CSF\u2010supported combination chemotherapy, LSG15, for adult T\u2010cell leukaemia\u2010lymphoma: Japan Clinical Oncology Group Study 9303"],"prefix":"10.1111","volume":"113","author":[{"given":"Yasuaki","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tomonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Tara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Kozuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Other Members Of The Lymphoma Study Group of The Japan Clini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.02338.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257742"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1748"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506293322603"},{"key":"e_1_2_6_6_1","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas","volume":"92","author":"Gisselbrecht C.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506293322604"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01050267"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990812)82:4<599::AID-IJC21>3.0.CO;2-R"},{"key":"e_1_2_6_10_1","volume-title":"New York, NY.","author":"Kalbfleish J.D.","year":"1980"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701002"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/blood.V76.10.2065.2065","article-title":"Expression of P\u2010glycoprotein in adult T\u2010cell leukemia cells","volume":"76","author":"Kuwazuru Y.","year":"1990","journal-title":"Blood"},{"key":"e_1_2_6_13_1","first-page":"227","article-title":"Final results of cooperative study of VEPA [vincristine, cyclophosphamide (Endoxan), prednisolone and adriamycin] therapy in advanced adult non\u2010Hodgkin's lymphoma: Relation between T\u2010 or B\u2010cell phenotype and response","volume":"12","author":"Lymphoma Study Group","year":"1982","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"e_1_2_6_14_1","first-page":"1518","article-title":"Phase II study with methyl\u20106 [[(2\u2010chloroethyl) nitrosoamino] carbonyl] amino]\u20106\u2010deoxy\u2010 alpha\u2010d\u2010glucopyranoside (MCNU) in hematological malignancies","volume":"10","author":"Matsuoka T.","year":"1983","journal-title":"Gan to Kagaku Ryoho [in Japanese]"},{"key":"e_1_2_6_15_1","first-page":"2145","article-title":"Phase II study of carboplatin in malignant lymphoma","volume":"15","author":"Naito K.","year":"1988","journal-title":"Gan to Kagaku Ryoho [in Japanese]"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930401)71:7<2217::AID-CNCR2820710709>3.0.CO;2-8"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_6_18_1","first-page":"961","article-title":"Biologic activity of MCNU: a new antitumor agent","volume":"63","author":"Sekido S.","year":"1979","journal-title":"Cancer Treatment Reports"},{"key":"e_1_2_6_19_1","first-page":"p43","volume-title":"Advances in Adult T\u2010Cell Leukemia and HTLV\u2010I Research Gann. Monograph on Cancer Research No 39","author":"Shimoyama M.","year":"1992"},{"key":"e_1_2_6_20_1","first-page":"p221","volume-title":"Adult T\u2010Cell Leukemia","author":"Shimoyama M.","year":"1994"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.1988.6.1.128","article-title":"Chemotherapeutic results and prognostic factors of patients with advanced non\u2010Hodgkin's lymphoma treated with VEPA or VEPA\u2010M","volume":"6","author":"Shimoyama M.","year":"1988","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.1988.6.7.1088","article-title":"Major prognostic factors of adult patients with advanced T\u2010cell lymphoma\/leukemia","volume":"6","author":"Shimoyama M.","year":"1988","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"e_1_2_6_24_1","first-page":"441","article-title":"Treatment of adult T cell leukemia with mega\u2010dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation","volume":"2","author":"Sobue R.","year":"1987","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199606010-00012"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910450206"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910410406"},{"key":"e_1_2_6_28_1","first-page":"164","article-title":"Phase I study of YK\u2010176 (2\u2032\u2010Deoxycoformycin) in patients with adult T\u2010cell leukemia\u2010lymphoma","volume":"22","author":"Tobinai K.","year":"1992","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jjco.a039642"},{"key":"e_1_2_6_30_1","first-page":"378","article-title":"Japan Clinical Oncology Group (JCOG) trial of second\u2010generation \u2018LSG4 protocol\u2019 in aggressive lymphoma including ATL: Prognostic factors and a predictive model (Abstract)","volume":"13","author":"Tobinai K.","year":"1994","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"e_1_2_6_31_1","first-page":"390","article-title":"Deoxycoformycin\u2010containing combination chemotherapy for adult T\u2010cell leukemia\u2010lymphoma: Japan Clinical Oncology Group (JCOG) Study #9109 (Abstract)","volume":"14","author":"Tobinai K.","year":"1995","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.394"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V50.3.481.481"},{"key":"e_1_2_6_34_1","doi-asserted-by":"crossref","unstructured":"Utsunomiya A. Miyazaki Y. Takatsuka Y. Hanada S. Uozumi K. Yashiki S. Tara M. Kawano F. Saburi Y. Kikuchi H. Hara M. Sao H. Morishima Y. Kodera S. Sonoda S. Tomonaga M.(2001)Improved outcome of adult T\u2010cell leukemia\/lymphoma by allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplantation 27 15\u201320.","DOI":"10.1038\/sj.bmt.1702731"},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","article-title":"The interleukin\u20102 receptor: a target for monoclonal antibody treatment of human T\u2010cell lymphotrophic virus I\u2010 induced adult T\u2010cell leukemia","volume":"82","author":"Waldmann T.A.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_36_1","first-page":"725","article-title":"Nitrosourea pharmacodynamics in relation to the central nervous system","volume":"60","author":"Walker M.D.","year":"1976","journal-title":"Cancer Treatment Reports"},{"key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1200\/JCO.1985.3.6.782","article-title":"Adult T\u2010cell leukemia with atypical surface phenotypes: Clinical correlation","volume":"3","author":"Yamada Y.","year":"1985","journal-title":"Journal of Clinical Oncology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02737.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02737.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02737.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T21:35:50Z","timestamp":1697578550000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02737.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02737.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02737.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]},"assertion":[{"value":"2002-01-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}